| Literature DB >> 33638292 |
Rosemary Sutton1,2, Luciano Dalla Pozza3, Seong Lin Khaw4, Chris Fraser5, Tom Revesz6,7, Janis Chamberlain8, Richard Mitchell2,9, Toby N Trahair1,2,9, Caroline M Bateman3, Nicola C Venn1, Tamara Law1, Erika Ong1, Susan L Heatley7,10, Barbara J McClure7,10, Claus Meyer11, Rolf Marschalek11, Michelle J Henderson1,2, Siobhan Cross12, Deborah L White7,10,13, Rishi S Kotecha14,15,16.
Abstract
We report on the Australian experience of blinatumomab for treatment of 24 children with relapsed/refractory precursor B-cell acute lymphoblastic leukaemia (B-ALL) and high-risk genetics, resulting in a minimal residual disease (MRD) response rate of 58%, 2-year progression-free survival (PFS) of 39% and 2-year overall survival of 63%. In total, 83% (n = 20/24) proceeded to haematopoietic stem cell transplant, directly after blinatumomab (n = 12) or following additional salvage therapy (n = 8). Four patients successfully received CD19-directed chimeric antigen receptor T-cell therapy despite prior blinatumomab exposure. Inferior 2-year PFS was associated with MRD positivity (20%, n = 15) and in KMT2A-rearranged infants (15%, n = 9). Our findings highlight that not all children with relapsed/refractory B-ALL respond to blinatumomab and factors such as blast genotype may affect prognosis.Entities:
Keywords: acute lymphoblastic leukaemia; blinatumomab; paediatric; refractory; relapse
Year: 2021 PMID： 33638292 DOI： 10.1002/pbc.28922
Source DB: PubMed Journal: Pediatr Blood Cancer ISSN： 1545-5009 Impact factor: 3.167